A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7; PMID:3127726; http://dx.doi.org/10.1038/332323a0
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5; PMID:3713831; http://dx.doi.org/10.1038/321522a0
   PubMed Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4; PMID:2247164; http://dx.doi.org/10.1038/348552a0
   PubMed Web of Science ®Google Scholar
• Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-25; PMID:16151405; http://dx.doi.org/10.1038/nbt1135
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81:6851-5; PMID:6436822; http://dx.doi.org/10.1073/pnas.81.21.6851
   PubMed Web of Science ®Google Scholar
• Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Dis 2007; 6:349-56; PMID:17431406; http://dx.doi.org/10.1038/nrd2241
   PubMed Web of Science ®Google Scholar
• Hwang YKH, and Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3-10; PMID:15848070; http://dx.doi.org/10.1016/j.ymeth.2005.01.001
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. mAbs 2010; 2:256-65; PMID:20400861; http://dx.doi.org/10.4161/mabs.2.3.11641
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lefranc MP. Human immunoglobulin allotypes: Possible implications for immunogenicity. mAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122
   PubMed Web of Science ®Google Scholar
• Grubb. R. Reaction of rheumatoid arthritic sera with a human antibody gamma globulin. Acta Rheumatol Scand 1956; 2:55-8; PMID:13424354; http://dx.doi.org/10.3109/rhe1.1956.2.issue-1-4.07
   PubMedGoogle Scholar
• Allen JC, Kunkel HG.. Antibodies to genetic types of gamma globulin after multiple transfusions. Science 1963; 139:418-9; PMID:14012122; http://dx.doi.org/10.1126/science.139.3553.418
   PubMed Web of Science ®Google Scholar
• Steinberg Ag, Wilson Ja. Hereditary globulin factors and immune tolerance in man. Science 1963; 140:303-4; PMID:13983708; http://dx.doi.org/10.1126/science.140.3564.303
   PubMed Web of Science ®Google Scholar
• Fudenberg HH., Fudenberg BR. Antibody to hereditary human gamma-globulin (gm) factor resulting from maternal-fetal incompatibility. Science 1964; 145:170-1; PMID:14171557; http://dx.doi.org/10.1126/science.145.3628.170
   PubMed Web of Science ®Google Scholar
• Oudin J. [The allotype of certain blood protein antigens]. C R Hebd Seances Acad Sci 1956; 242:2606-8; PMID:13343562
   PubMedGoogle Scholar
• de Lange GG. Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogen 1989; 6:7-17; PMID:2698222
   PubMedGoogle Scholar
• WHO. Review of the notation for the allotypic and related markers of human immunoglogulins. J Immunol 1976; 117:1056-8; PMID:956649
   PubMedGoogle Scholar
• Chan AC, & Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Meltzer M, Franklin EC, Fundenberg H, Frangione B. Signal peptide differences between gamma-globulins of different genetic (gm) types. Proc Natl Acad Sci U S A 1964; 51:1007-14; PMID:14218064; http://dx.doi.org/10.1073/pnas.51.6.1007
   PubMed Web of Science ®Google Scholar
• Frangione, B., Franklin EC, Fudenberg HH, and Koshland ME. Structural studies of human gamma-G-myeloma proteins of different antigenic subgroups and genetic specificities. J Exp Med 1966; 124:715-32; PMID:4162448; http://dx.doi.org/10.1084/jem.124.4.715
   PubMed Web of Science ®Google Scholar
• Press EM, Hogg NM. The amino acid sequences of the fd fragments of two human gamma-1 heavy chains. Biochem J 1970; 117:641-60; PMID:5449120; http://dx.doi.org/10.1042/bj1170641
   PubMed Web of Science ®Google Scholar
• Johnson WE, Kohn PH, Steinberg AG. Population genetics of the human allotypes Gm, Inv, and A2m. Clin Immunol Immunopathol 1977; 7:97-113; PMID:404106; http://dx.doi.org/10.1016/0090-1229(77)90034-4
   PubMedGoogle Scholar
• Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, Ohresser M, Degenne D, Dugoujon JM, Jefferis R, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogen Gen 2009; 19:383-7; PMID:19319024; http://dx.doi.org/10.1097/FPC.0b013e32832a06bf
   PubMed Web of Science ®Google Scholar
• Bartelds GM, de Groot E, Nurmohamed MT, Hart MHL, van Eede PH, Wijbrandts CA, Crusius JBA, Dijkmans BAC, Tak, PP, Aarden L, Wolbink GJ. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: A cohort study. Arthritis Res Ther 2010; 12:R221; PMID:21187010; http://dx.doi.org/10.1186/ar3208
   PubMed Web of Science ®Google Scholar
• Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007; 10:219-27; PMID:17436557
   PubMed Web of Science ®Google Scholar
• Kropshofer H, Spindeldreher S, Rohn TA, Platania N, Grygar C, Daniel N, Wolpl A, Langen H, Horejsi V, Vogt AB. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat Immunol 2002; 3:61-8; PMID:11743588; http://dx.doi.org/10.1038/ni750
   PubMed Web of Science ®Google Scholar
• Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, Krieg J, Djidja MC, Baban A, Spindeldreher S, et al. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS One [Electronic Resource] 2014; 9:e86322; PMID:24466023; http://dx.doi.org/10.1371/journal.pone.0086322
   PubMed Web of Science ®Google Scholar
• Rohn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H. A novel strategy for the discovery of MHC class II-restricted tumor antigens: Identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005; 65:10068-78; PMID:16267033; http://dx.doi.org/10.1158/0008-5472.CAN-05-1973
   PubMed Web of Science ®Google Scholar
• Barker S. Immunogenicity of biotherapeutics: A need for consensus on flexibility of approach. Curr Drug Safety 2010; 5:272-4; PMID:20925649; http://dx.doi.org/10.2174/157488610792245975
   PubMedGoogle Scholar
• Kropshofer H, Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J Immunotoxicol 2006; 3:131-6; PMID:18958693; http://dx.doi.org/10.1080/15476910600845625
   PubMedGoogle Scholar
• Perry LC, Jones TD, Baker MP. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs in R & D 2008; 9:385-96; PMID:18989990; http://dx.doi.org/10.2165/0126839-200809060-00004
   PubMedGoogle Scholar
• Stickler MM, Reddy A, Xiong JM, Hinton PR, DuBridge R, Harding FA. The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Gene Immunity 2011; 12:213-21; PMID:21326320; http://dx.doi.org/10.1038/gene.2010.68
   PubMed Web of Science ®Google Scholar
• Carter, P., Presta, L., Gorman CM, Ridgway JBB, Henner, D., Wong WLT, Rowland AM., Kotts, C., Carver ME, Shepard HM.,. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proe Natl Acad Sc USA 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9-18; PMID:9073061; http://dx.doi.org/10.1016/S0378-1119(96)00628-2
   PubMed Web of Science ®Google Scholar
• Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JS, Baker MP. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemostasis 2005; 3:991-1000; PMID:15869596; http://dx.doi.org/10.1111/j.1538-7836.2005.01309.x
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Pommie C, Kaas Q, Duprat E, Bosc N, Guiraudou D, Jean C, Ruiz M, Da Piedade I, Rouard M, et al. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev Comp Immunol 2005; 29:185-203; PMID:15572068; http://dx.doi.org/10.1016/j.dci.2004.07.003
   PubMed Web of Science ®Google Scholar
• Lefranc, G., Lefranc, M.-P. The Immunoglobulin Factsbook. London: Academic Press, 2001.
   Google Scholar